Drugs / MT1011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07024160 | Jun 2025 → Apr 2026 overdue | — | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT1011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07024160 ↗ |
| Modality | Small molecule | “novel synthetic small molecule anticoagulant reversal agent” NCT07024160 ↗ |